Scott S. Tykodi, MD, PhD

home / authors / scott-s-tykodi-md-phd

Scott Tykodi, MD, PhD, is an associate professor in the Clinical Research Division and an affiliate investigator in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center.

Articles

Scott Tykodi, MD, PhD

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

Scott S. Tykodi, MD, PhD
May 20th 2025

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Read More

Scott Tykodi, MD, PhD

Dr Tykodi on Long-Term Outcomes for Nivolumab Plus Ipilimumab in Favorable-Risk Advanced RCC

Scott S. Tykodi, MD, PhD
April 22nd 2025

Scott Tykodi, MD, PhD, discusses data from CheckMate 214 for nivolumab plus ipilimumab vs sunitinib in favorable-risk advanced RCC.

Read More

Dr Tykodi on the Selection Between IO/IO and IO/TKI Combinations in Frontline Advanced Clear Cell RCC

Dr Tykodi on the Selection Between IO/IO and IO/TKI Combinations in Frontline Advanced Clear Cell RCC

Scott S. Tykodi, MD, PhD
April 15th 2025

Scott Tykodi, MD, PhD, discusses key clinical considerations that informing selection between IO/IO and IO/TKI combinations in advanced renal cell carcinoma.

Read More

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC

Scott S. Tykodi, MD, PhD
August 11th 2020

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

Read More

Dr. Tykodi on the Clinical Implications of the KEYNOTE-427 Trial in Advanced RCC

Dr. Tykodi on the Clinical Implications of the KEYNOTE-427 Trial in Advanced RCC

Scott S. Tykodi, MD, PhD
August 10th 2020

Scott S. Tykodi, MD, PhD, discusses the clinical implications of the phase 2 KEYNOTE-427 trial in advanced renal cell carcinoma.

Read More

Dr. Tykodi on the Efficacy of Dual Checkpoint Blockade in RCC

Dr. Tykodi on the Efficacy of Dual Checkpoint Blockade in RCC

Scott S. Tykodi, MD, PhD
June 25th 2020

Scott S. Tykodi, MD, PhD, discusses the efficacy of dual checkpoint blockade in renal cell carcinoma.

Read More

Latest Updated Articles

Alexis LeVee, MD
Published: May 14th 2025 | Updated: May 30th 2025
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer